Anti-Fibrinolytic Drugs - Guatemala

In Guatemala, the revenue in the Anti-Fibrinolytic Drugs market is estimated to reach US$6.80m by 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 5.16%, leading to a market volume of US$8.75m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$9.86bn in 2024.
Guatemala's market for anti-fibrinolytic drugs is experiencing steady growth due to increasing awareness and demand for effective treatments in the country.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Guatemala has been showing steady growth in recent years.

Customer preferences: Guatemalan customers have been increasingly seeking out Anti-Fibrinolytic Drugs due to rising incidences of bleeding disorders and surgical procedures. Additionally, the affordability of these drugs compared to other treatment options has made them a popular choice among the population.

Trends in the market: The Anti-Fibrinolytic Drugs market in Guatemala has seen a rise in demand due to the increasing number of surgeries being performed in the country. As the healthcare infrastructure continues to develop, more complex surgical procedures are being offered, leading to a greater need for Anti-Fibrinolytic Drugs to prevent excessive bleeding during and after surgery. Additionally, the market has seen an increase in the number of local manufacturers producing these drugs, leading to greater availability and lower prices.

Local special circumstances: One of the key factors driving the growth of the Anti-Fibrinolytic Drugs market in Guatemala is the country's high incidence of bleeding disorders. Guatemala has one of the highest rates of hemophilia in the world, with an estimated 1,200 people living with the condition. This has led to a greater demand for Anti-Fibrinolytic Drugs, which are used to treat bleeding disorders.

Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in Guatemala is also being driven by broader macroeconomic trends in the country. Guatemala has been experiencing steady economic growth in recent years, which has led to an increase in healthcare spending. Additionally, the country has been investing in its healthcare infrastructure, which has led to the development of more advanced surgical procedures and greater demand for Anti-Fibrinolytic Drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.